Hims & Hers begins selling branded GLP-1s in Australia

Hims & Hers said on August 31 that it has begun offering branded GLP-1 weight-loss drugs and men's health treatments in Australia, marking its first move into the Asia-Pacific region ^[1]. The rollout follows the company's acquisition of Sydney-based digital health platform Eucalyptus, which owns the men's health brand Pilot and the women's health brand Juniper ^[1][2].

Pilot will now operate under the Hims umbrella, offering products from sexual health medications to cholesterol treatments, according to former Eucalyptus CEO Tim Doyle, who is now a senior vice president at Hims & Hers ^[1]. A company spokesperson said the Australian weight-loss program may include access to branded GLP-1 medications, the same category Hims sells in the U.S. under names like Wegovy, made by Novo Nordisk, and Zepbound, made by Eli Lilly ^[1][2]. Existing Pilot clinicians are being transitioned onto the Hims platform, and care-team access will extend to 24 hours a day ^[1]. Women's health services are planned for later this year through the Juniper brand ^[1].

Doyle said the expansion should ease access to preventative care and cut travel and wait times for patients, pointing to rural access as "a big factor in Australia" ^[1]. Hims has set a goal of $6.5 billion in revenue by 2030 and has been investing in diagnostics, manufacturing, hormonal treatments, and international markets to get there ^[1]. International business has already helped raise monthly revenue per subscriber by 21% year over year compared with the prior year, though it has also pressured gross profit margins ^[1][2]. Hims has said during its second-quarter earnings call that it expects gross margins to stay below historical levels as it accelerates international offerings ^[1]. The company made a similar move into Europe in 2025 when it acquired Zava, a London-based company that prescribes and delivers weight-loss drugs in the U.K., Germany, France, and Ireland ^[1].

Why it matters for patients

For patients in Australia, the change means Pilot's existing weight-loss and men's health services are being folded into Hims' broader platform, with the promise of round-the-clock care-team access and, eventually, combined services that were previously purchased separately ^[1][2]. Doyle said the goal is to reduce the difficulty some Australians face reaching care because of distance from clinics ^[1].

For U.S. patients, the news is a reminder that Hims & Hers' domestic GLP-1 business now runs on branded resale of drugs like Wegovy and Zepbound rather than the compounded semaglutide it sold before exiting that market, a shift described as lower-margin for the company ^[1]. Analysts covering the stock note that international growth, including Australia, is adding revenue but not yet adding profit, since gross margins are expected to stay below historical levels while the company invests abroad ^[1][2]. This does not change drug pricing or coverage in the U.S. today, but it shows how Hims & Hers is trying to grow its overall business at a time when its core American GLP-1 model has become less profitable ^[1][2].

What happens next

Hims has said it plans to launch women's health services in Australia later in 2026 through the Juniper brand ^[1]. The company has not detailed a timeline for when its international expansion, including Australia, might reach the scale needed to improve profit margins, and analysts say subscriber growth, revenue per subscriber, and margin trends in these markets will be the numbers to watch ^[2]. Hims' long-term target remains $6.5 billion in revenue by 2030 ^[1][2].